These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 33669447

  • 21. S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma.
    Reeb AN, Li W, Sewell W, Marlow LA, Tun HW, Smallridge RC, Copland JA, Spradling K, Chernock R, Lin RY.
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E232-42. PubMed ID: 25423568
    [Abstract] [Full Text] [Related]

  • 22. Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer.
    Antognelli C, Moretti S, Frosini R, Puxeddu E, Sidoni A, Talesa VN.
    Cells; 2019 Jun 06; 8(6):. PubMed ID: 31174324
    [Abstract] [Full Text] [Related]

  • 23. The mechanism of radiosensitization by YM155, a novel small molecule inhibitor of survivin expression, is associated with DNA damage repair.
    Hu S, Fu S, Xu X, Chen L, Xu J, Li B, Qu Y, Yu H, Lu S, Li W.
    Cell Physiol Biochem; 2015 Jun 06; 37(3):1219-30. PubMed ID: 26418254
    [Abstract] [Full Text] [Related]

  • 24. Quinone-Based Antitumor Agent Sepantronium Bromide (YM155) Causes Oxygen-Independent Redox-Activated Oxidative DNA Damage.
    Wani TH, Surendran S, Jana A, Chakrabarty A, Chowdhury G.
    Chem Res Toxicol; 2018 Jul 16; 31(7):612-618. PubMed ID: 29897742
    [Abstract] [Full Text] [Related]

  • 25. Ovatodiolide isolated from Anisomeles indica induces cell cycle G2/M arrest and apoptosis via a ROS-dependent ATM/ATR signaling pathways.
    Yu CY, Jerry Teng CL, Hung PS, Cheng CC, Hsu SL, Hwang GY, Tzeng YM.
    Eur J Pharmacol; 2018 Jan 15; 819():16-29. PubMed ID: 28986085
    [Abstract] [Full Text] [Related]

  • 26. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J, Gokare P, Gallant JN, Dicker D, Whitcomb T, Cooper T, Liao J, Derr J, Liu J, Goldenberg D, Finnberg NK, El-Deiry WS.
    Clin Cancer Res; 2016 Dec 15; 22(24):6192-6203. PubMed ID: 27307592
    [Abstract] [Full Text] [Related]

  • 27. Exosome-mediated delivery of SCD-1 siRNA promoted the death of anaplastic thyroid carcinoma cells via regulating ROS level.
    Wang MH, Ye Y, Zhang M, Zhou BR, Wang JN, Song YN, Xia W.
    Clin Transl Oncol; 2022 Feb 15; 24(2):288-296. PubMed ID: 34287816
    [Abstract] [Full Text] [Related]

  • 28. Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models.
    Pinto N, Prokopec SD, Ghasemi F, Meens J, Ruicci KM, Khan IM, Mundi N, Patel K, Han MW, Yoo J, Fung K, MacNeil D, Mymryk JS, Datti A, Barrett JW, Boutros PC, Ailles L, Nichols AC.
    PLoS One; 2020 Feb 15; 15(9):e0239315. PubMed ID: 32970704
    [Abstract] [Full Text] [Related]

  • 29. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
    Oh JM, Baek SH, Gangadaran P, Hong CM, Rajendran RL, Lee HW, Zhu L, Gopal A, Kalimuthu S, Jeong SY, Lee SW, Lee J, Ahn BC.
    Thyroid; 2020 Apr 15; 30(4):501-518. PubMed ID: 31928162
    [Abstract] [Full Text] [Related]

  • 30. The mechanistic effects of the dioxonaphthoimidazolium analog YM155 in renal cell carcinoma cell cycling and apoptosis.
    Sim MY, Go ML, Yuen JSP.
    Life Sci; 2018 Jun 15; 203():282-290. PubMed ID: 29689274
    [Abstract] [Full Text] [Related]

  • 31. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
    von Roemeling CA, Marlow LA, Pinkerton AB, Crist A, Miller J, Tun HW, Smallridge RC, Copland JA.
    J Clin Endocrinol Metab; 2015 May 15; 100(5):E697-709. PubMed ID: 25675381
    [Abstract] [Full Text] [Related]

  • 32. Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: Involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation.
    Chang JW, Kang SU, Choi JW, Shin YS, Baek SJ, Lee SH, Kim CH.
    Free Radic Biol Med; 2014 Feb 15; 67():115-30. PubMed ID: 24216474
    [Abstract] [Full Text] [Related]

  • 33. Disrupting glycolysis and DNA repair in anaplastic thyroid cancer with nucleus-targeting platinum nanoclusters.
    Pan Z, Lu X, Hu X, Yu R, Che Y, Wang J, Xiao L, Chen J, Yi X, Tan Z, Li F, Ling D, Huang P, Ge M.
    J Control Release; 2024 May 15; 369():517-530. PubMed ID: 38569942
    [Abstract] [Full Text] [Related]

  • 34. PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.
    Che HY, Guo HY, Si XW, You QY, Lou WY.
    Tumour Biol; 2014 Sep 15; 35(9):8659-64. PubMed ID: 24867098
    [Abstract] [Full Text] [Related]

  • 35. YM155 inhibits topoisomerase function.
    Hong M, Ren MQ, Silva J, Paul A, Wilson WD, Schroeder C, Weinberger P, Janik J, Hao Z.
    Anticancer Drugs; 2017 Feb 15; 28(2):142-152. PubMed ID: 27754993
    [Abstract] [Full Text] [Related]

  • 36. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM, Roelli MA, Forster S, Wasmer MH, Brühl F, Maire RS, Di Pancrazio S, Ruepp MD, Giger R, Perren A, Schmitt AM, Krebs P, Charles RP, Dettmer MS.
    Thyroid; 2019 Jul 15; 29(7):979-992. PubMed ID: 30938231
    [Abstract] [Full Text] [Related]

  • 37. YM155 and BIRC5 downregulation induce genomic instability via autophagy-mediated ROS production and inhibition in DNA repair.
    Cheng SM, Lin TY, Chang YC, Lin IW, Leung E, Cheung CHA.
    Pharmacol Res; 2021 Apr 15; 166():105474. PubMed ID: 33549731
    [Abstract] [Full Text] [Related]

  • 38. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
    Mehta A, Zhang L, Boufraqech M, Zhang Y, Patel D, Shen M, Kebebew E.
    Endocr Relat Cancer; 2015 Jun 15; 22(3):319-29. PubMed ID: 25972243
    [Abstract] [Full Text] [Related]

  • 39. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.
    Mir R, Stanzani E, Martinez-Soler F, Villanueva A, Vidal A, Condom E, Ponce J, Gil J, Tortosa A, Giménez-Bonafé P.
    Gynecol Oncol; 2014 Jan 15; 132(1):211-20. PubMed ID: 24262875
    [Abstract] [Full Text] [Related]

  • 40. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
    Lin SF, Lin JD, Chou TC, Huang YY, Wong RJ.
    PLoS One; 2013 Jan 15; 8(10):e77684. PubMed ID: 24155971
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.